AMERICAN HOME PRODUCTS LICENSES INTO AIDS DRUG DEVELOPMENT
AMERICAN HOME PRODUCTS LICENSES INTO AIDS DRUG DEVELOPMENT: First AHP product in clinicals will be AS-101. AHP announced March 16 that it has acquired exclusive worldwide rights to AS-101 via a license with a joint venture of National Patent Development Corp. and Bar-Ilan University of Israel. AHP is assuming responsibility for development and marketing of the compound. AHP noted that an IND has been approved for study of the drug in AIDS patients. Clinical trials with AS-101 are expected to begin at an undisclosed "major medical center" in New York City within a month to six weeks. AHP says that human studies in France, Israel, and Mexico are ongoing in AIDS and "certain forms of cancer." The National Institute of Allergy & Infectious Diseases is also interest in AS-101. NIAID said it is "actively considering studying" the immunomodulator. The final protocol for a Phase I dose ranging study in AIDS patients has been approved and an IND is "in the process" of being filed, NIAID said. Under the terms of the agreement, AHP explained, the joint venture company, NPDC-AS101, will manufacture "the principal ingredient of the drug and American Home Products will make upfront payments, additional progress payments and pay a royalty on net sales."
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth